Author:
Géraldine DESCAMPS,Journe Fabrice,Sven Saussez
Abstract
Today, immunohistochemical markers are routinely used alone or in association to examine thyroid lesions
but without sufficient sensitivity and specificity regarding to cancer diagnosis. Additional markers are
currently identified among genetic alterations or miRNA panels carrying significant diagnostic values.
Combining immunostaining data, mutation status, gene rearrangement and miRNA expression should help
to define an integrative signature for the accurate diagnosis of thyroid carcinomas.
Subject
Industrial and Manufacturing Engineering,Metals and Alloys,Strategy and Management,Mechanical Engineering
Reference44 articles.
1. Durante C, Costante G, Lucisano G, Bruno R, Meringolo D et al. (2015) The natural history of benign thyroid nodules. JAMA 313: 926-935. [Crossref]
2. Taye A, Gurciullo D, Miles BA, Gupta A, Owen RP et al. (2018) Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules. Surgery 163: 97-103. [Crossref]
3. Gharib H, Papini E (2007) Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am 36: 707-735. [Crossref]
4. Mataraci EA, Ozgüven BY, Kabukçuoglu F (2012) Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions. Pol J Pathol 63: 58-64. [Crossref]
5. Liu Z, Li X, Shi L, Maimaiti Y, Chen T et al. (2014) Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med 7: 2304-2308. [Crossref]
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献